Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Double-blind, Randomized Study of AMG 145 Versus Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects
2012-001364-30Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in hypercholesterolemia and dyslipidemia (3 arms), sponsored by Amgen. Primary endpoints: Percent change from baseline in LDL-C at 12 weeks and Safety and tolerability of AMG 145 versus ezetimibe. Started Aug 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on 2012-001364-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001364-30.